Ranimustine

Drugbox
IUPAC_name = 1-(2-chloroethyl)-1-nitroso-3-( [(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-methoxyoxan-2-yl] methyl)urea


CAS_number = 58994-96-0
CAS_supplemental =
ATC_prefix =
ATC_suffix =
ATC_supplemental =
PubChem = 71741
DrugBank =
chemical_formula =
C=10 | H=18 | Cl=1 | N=3 | O=7
molecular_weight = 327.71 g/mol
smiles = CO [C@@H] 1 [C@@H] ( [C@H] ( [C@@H] ( [C@H] (O1)CNC(=O)N(CCCl)N=O)O)O)O
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status = Rx-only
routes_of_administration = IV

Ranimustine (INN, marketed under the tradename Cymerin; also known as MCNU) is a nitrosourea alkylating agent approved in Japan for the treatment of chronic myelogenous leukemiacite journal |author=Kitajima K, Adachi T, Takahashi I, "et al" |title= [Chemotherapy of chronic myelogenous leukemia--VP(M) regimen initiated during its chronic phase, and evaluation of MCNU in the phase of blastic crisis] |language=Japanese |journal=Gan To Kagaku Ryoho |volume=16 |issue=11 |pages=3573–9 |year=1989 |month=November |pmid=2817908 |doi= |url=] and polycythemia vera.cite journal |author=Nagai M, Tasaka T, Kamano H, "et al" |title= [Therapeutic effect of ranimustine (MCNU) on essential thrombocythemia and polycythemia vera] |language=Japanese |journal=Gan To Kagaku Ryoho |volume=15 |issue=12 |pages=3267–70 |year=1988 |month=December |pmid=3196045 |doi= |url=]

It has never been filed for FDA evaluation in the United States, where it is not marketed.

References

* [http://di.mt-pharma.co.jp/file/dc/cmr_a.pdf Cymerin サイメリン] (PDF) Mitsubishi Tanabe Pharma. October 2007.